The InGeNA Board is thrilled to announce Erin Evans as the incoming CEO, beginning her tenure in July 2024. Erin brings a wealth of experience and a track record of success, having served as CEO of Life Sciences Qld, where she spearheaded transformative initiatives that significantly enhanced the organisation’s impact and visibility. Her extensive career spans diverse sectors, including industry, academia, and entrepreneurship where she is co-founder of a successful start-up.

Erin has actively contributed to genomics steering committees since 2013 and chaired Health Consumers Queensland, demonstrating her commitment to patient-centric approaches in healthcare.

Reflecting on this appointment, InGeNA Board Chair Kathy Campbell remarked, “In this era of ground-breaking advancements in genomics, we are thrilled to welcome Erin Evans as our new CEO. Her appointment signifies a pivotal moment for InGeNA, aligning with our mission to drive innovation and accessibility in genomics for the benefit of all Australians. Erin’s expertise and passion for precision medicine make her the ideal leader to guide us into a future where genomics plays a central role in transforming healthcare outcomes. We look forward to the positive impact her leadership will bring to our organisation and the broader genomics community.”

Erin expressed her enthusiasm stating, “I am honoured and thrilled to take on the role of InGeNA CEO, returning to my passion for genomics at a crucial juncture in healthcare and technology. The future of health lies in precision medicine, aimed at enhancing the well-being of all individuals. The synergy between industry, government, and consumers is paramount in realising this vision, making this opportunity incredibly important and exciting.”

With a PhD in Biotechnology from the University of Queensland and an MBA from Henley Business School (University of Reading), Erin brings a unique blend of scientific expertise and strategic acumen to the CEO role. She looks forward to engaging with members and stakeholders to champion accessible and equitable genomics health solutions for all Australians.